L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
B-Cell Acute Lymphoblastic Leukemia
Explore 136 assets in B-Cell Acute Lymphoblastic Leukemia →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Stanford University
Modality
protein_peptide
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03233854CT.gov CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) (this asset) | Stanford University | P1 | C · 39 |
| Etoposide | University of Washington | P3 | BBB |
| Vincristine Sulfate | City of Hope Medical Center | P3 | BB |
| Crisantaspase | City of Hope Medical Center | P3 | BB |
| Nivestim | University of Washington | P3 | BB |
| Dasatinib | National Cancer Institute (NCI) | P3 | BB |
| Pegaspargase | National Cancer Institute (NCI) | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Dexasone | SWOG Cancer Research Network | P3 | BB |
+42 more in the B-Cell Acute Lymphoblastic Leukemia cohort
Other indications for L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P2/3 | CCC · 53 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2/3 | CCC · 53 |
| Lung Cancer | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) in B-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-methionyl-interleukin-15-human-non-glycosylated-produced-in-escherichia-coli-substituted-on-an-average-of-one-site-among-n2-of-met1-andor-n6-of-lysyl-residues-with-4-alpha-methylpolyoxyethylene-omega-oxybutanoyl-groups-40-kda-each-b-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →